PURPOSE: To determine the effect of an acute dose of 0.005% latanoprost on intraocular pressure and pulsatile ocular blood flow in normal eyes. METHODS:Nineteen volunteers received a single dose (two drops) of latanoprost 0.005% in one eye and placebo in the fellow control eye, randomized and masked to the observer. Intraocular pressure, perfusion pressure, pulsatile ocular blood flow, and systemic circulatory parameters were measured before and 8 hours after dosing. RESULTS: The mean (+/- SE) intraocular pressure, perfusion pressure, and pulsatile ocular blood flow before treatment were 17 +/- 1 mm Hg, 46 +/- 3 mm Hg, and 13 +/- 1 microl per second, respectively, in both the treated and control eyes. The mean intraocular pressure reduction was 4.9 and 2.1 mm Hg (28% and 12%) in the treated and fellow eye, respectively. The mean perfusion pressure increase was 5.6 and 2.8 mm Hg (12% and 6%) in the treated and fellow eye, respectively. The mean pulsatile ocular blood flow increase was 2.7 and 0.2 microl per second (20% and 1%) in the treated and fellow eye, respectively. The treated eye change in pulsatile ocular blood flow was not correlated to the change in perfusion pressure. Simultaneous reduction of intraocular pressure and increase or no significant change in pulsatile ocular blood flow occurred in 15 of 19 (79%) of the treated eyes. The systemic blood pressure and pulse rates remained in normal ranges over the 8-hour period. CONCLUSION: In this study, topical latanoprost significantly reduces intraocular pressure and increases ocular blood flow in normal eyes 8 hours after dosing. These effects of latanoprost may be beneficial in the management of glaucoma patients.
RCT Entities:
PURPOSE: To determine the effect of an acute dose of 0.005% latanoprost on intraocular pressure and pulsatile ocular blood flow in normal eyes. METHODS: Nineteen volunteers received a single dose (two drops) of latanoprost 0.005% in one eye and placebo in the fellow control eye, randomized and masked to the observer. Intraocular pressure, perfusion pressure, pulsatile ocular blood flow, and systemic circulatory parameters were measured before and 8 hours after dosing. RESULTS: The mean (+/- SE) intraocular pressure, perfusion pressure, and pulsatile ocular blood flow before treatment were 17 +/- 1 mm Hg, 46 +/- 3 mm Hg, and 13 +/- 1 microl per second, respectively, in both the treated and control eyes. The mean intraocular pressure reduction was 4.9 and 2.1 mm Hg (28% and 12%) in the treated and fellow eye, respectively. The mean perfusion pressure increase was 5.6 and 2.8 mm Hg (12% and 6%) in the treated and fellow eye, respectively. The mean pulsatile ocular blood flow increase was 2.7 and 0.2 microl per second (20% and 1%) in the treated and fellow eye, respectively. The treated eye change in pulsatile ocular blood flow was not correlated to the change in perfusion pressure. Simultaneous reduction of intraocular pressure and increase or no significant change in pulsatile ocular blood flow occurred in 15 of 19 (79%) of the treated eyes. The systemic blood pressure and pulse rates remained in normal ranges over the 8-hour period. CONCLUSION: In this study, topical latanoprost significantly reduces intraocular pressure and increases ocular blood flow in normal eyes 8 hours after dosing. These effects of latanoprost may be beneficial in the management of glaucomapatients.
Authors: Katarzyna Konieczka; Simone Koch; Daniela Hauenstein; Thomas Navin Chackathayil; Tatjana Binggeli; Andreas Schoetzau; Josef Flammer Journal: Transl Vis Sci Technol Date: 2019-06-21 Impact factor: 3.283